Drugs Made In America Acquisition Corp. (DMAAR) Common Equity (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Common Equity for 3 consecutive years, with -$7.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 3.56% year-over-year to -$7.4 million; the trailing twelve-month figure through Jun 2026 stood at -$7.4 million (down 3.56% YoY), and the FY2025 full-year result was -$7.3 million, down 2866.77% from the prior year.
• Common Equity slipped to -$7.4 million in Q2 2026 per DMAAR's latest filing, from -$7.3 million in the prior quarter.
• Across five years, Common Equity topped out at -$244845.0 in Q4 2024 and bottomed at -$7.4 million in Q2 2026.
• Historically, Common Equity has averaged -$6.1 million across 3 years, with a median of -$7.2 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Common Equity sank 2866.77% in 2025, then slipped 3.56% in 2026.
• Over 3 years, Common Equity stood at -$244845.0 in 2024, then tumbled by 2866.77% to -$7.3 million in 2025, then fell by 1.96% to -$7.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$7.4 million, -$7.3 million, and -$7.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.